GlassScriptPhysician profile
Marshall G Howell
NPI 1164421848
$4,626.27
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $521 · 2021: $695 · 2022: $1,048 · 2023: $1,145 · 2024: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,583.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $824.64 | 2019-2024 | |
| Astellas Pharma US INC | $495.56 | 2019-2024 | Veozah, Myrbetriq |
| Ethicon US, LLC | $255.84 | 2019-2023 | Enseal X1 |
| Mayne Pharma Commercial LLC | $222.53 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $222.41 | 2023-2024 | Myfembree, Gemtesa |
| Amgen INC. | $197.75 | 2019-2023 | Prolia, Evenity |
| Aspira Women'S Health INC | $184.67 | 2023 | Ova1 |
| Pfizer INC. | $181.22 | 2019-2024 | |
| Biogen, INC. | $163.26 | 2024 | Zurzuvae |
| Avion Pharmaceuticals | $148.87 | 2020-2023 | Balcoltra |
| Medtronic, INC. | $132.94 | 2023 | V-Loc 180 |
| Sage Therapeutics, LLC | $132.78 | 2022-2023 | |
| Myovant Sciences INC. | $122.45 | 2021-2022 | |
| Daiichi Sankyo INC. | $119.75 | 2020-2022 | |
| Medical Device Business Services, INC. | $113.41 | 2019 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.